Pentadecapeptide (BPC Variant) Protocol
Pentadecapeptide refers to the class of 15-amino acid Body Protection Compound peptides derived from human gastric juice, primarily BPC-157 and its variant formulations. The term encompasses different salt forms (acetate for injection, arginine salt for oral stability), modified sequences, and combination approaches. These pentadecapeptides exhibit remarkable tissue-protective properties including wound healing acceleration, anti-inflammatory effects, gastrointestinal protection, neuroprotection, and pro-angiogenic activity through VEGF upregulation, NO system modulation, and FAK-paxillin pathway activation. This protocol covers both injectable (acetate) and oral (arginine salt) administration routes, comparative dosing, form selection guidance, and stacking for comprehensive tissue repair research.
Protocol Overview
- Compound
- Pentadecapeptide (BPC-157 variants)
- Category
- Tissue Repair / Gastric Protection
- Mechanism
- Multi-pathway tissue repair: VEGF upregulation, NO system modulation, FAK-paxillin pathway, anti-inflammatory cytokine modulation, gut-brain axis support
- Molecular Weight
- ~1,419 g/mol (BPC-157 free base)
- Forms
- Acetate salt (SubQ) | Arginine salt (oral, acid-stable)
- Route
- Subcutaneous and/or Oral
- Frequency
- 1-2x daily
- Cycle Length
- 4-8 weeks on, 2-4 weeks off
Dosing Protocol
| Protocol | Dose | Form | Frequency | Duration |
|---|---|---|---|---|
| SubQ Standard | 250 mcg | Acetate | 1-2x daily | 4-8 weeks |
| Oral Standard | 250-500 mcg | Arginine salt | 2x daily (empty stomach) | 4-8 weeks |
| Combined Protocol | 250 mcg SubQ + 250 mcg oral | Acetate + Arginine | 1x each daily | 4-8 weeks |
| High-Dose Repair | 500 mcg | Acetate | 2x daily near injury | 4-6 weeks |
Key principle: Choose form based on target: acetate (SubQ) for musculoskeletal injuries, systemic repair, and localized healing; arginine salt (oral) for GI conditions, gut barrier repair, and gut-brain axis modulation. The combined protocol provides maximal coverage across both systemic and GI pathways.
Form Selection Guide
Acetate Salt (Injectable)
- Best for: Musculoskeletal injuries, tendon/ligament repair
- Route: Subcutaneous, near injury site
- Reconstitution: 2mL BAC water per 5mg vial
- Advantage: Higher bioavailability, localized effect
- 250mcg dose: 10 units from 2.5mg/mL solution
Arginine Salt (Oral)
- Best for: GI repair, IBS, leaky gut, gut-brain axis
- Route: Oral, on empty stomach
- Form: Capsules or reconstituted in water
- Advantage: Survives stomach acid, GI tract exposure
- Note: Higher doses needed for systemic effects
Expected Timeline
Side Effects & Monitoring
Common Side Effects
- Injection site redness (SubQ, mild and transient)
- Mild nausea with oral form (uncommon)
- Slight drowsiness (rare)
BPC pentadecapeptides have shown no toxicity in extensive preclinical research. They are derived from naturally occurring gastric juice proteins with an exceptional safety profile.
Precautions
- Theoretical concern with active cancer (pro-angiogenic)
- Limited formal human clinical trial data
- Monitor for changes in blood pressure (NO modulation)
- Not recommended during pregnancy
Stacking Recommendations
Compatible Compounds
- TB-500: Complementary tissue repair pathway (thymosin)
- GHK-Cu: Collagen synthesis and wound healing
- AOD-9604: Fat loss without compromising healing
- Thymosin Alpha-1: Immune support alongside repair
- L-Glutamine: Gut barrier substrate support
Popular Stacks
- Injury Recovery: BPC 250mcg SubQ + TB-500 2mg 2x/wk
- Gut Healing: BPC oral 500mcg 2x/day + L-Glutamine 5g
- Full Repair: BPC SubQ + oral + GHK-Cu 200mcg
Blood Work Recommendations
| Panel | Markers | Timing |
|---|---|---|
| Inflammation | hs-CRP, ESR, IL-6 | Baseline, Week 4, Week 8 |
| GI Health | Zonulin, calprotectin (stool) | Baseline, Week 8 |
| Liver Function | ALT, AST, GGT | Baseline, Week 8 |
| General | CBC, CMP | Baseline, Week 8 |
Related Tools & Resources
Frequently Asked Questions
Pentadecapeptide literally means '15-amino acid peptide.' In the context of peptide research, it typically refers to BPC-157 (Body Protection Compound-157), a 15-amino acid peptide derived from human gastric juice protein BPC. The term 'pentadecapeptide' is often used in research literature and by suppliers as an alternative name, particularly for BPC-157 variants with different salt forms (acetate vs arginine salt) or modified sequences.
BPC-157 acetate is the most common form, suitable for subcutaneous injection. BPC-157 arginine salt (also called stable gastric pentadecapeptide or BPC-157 stable) is formulated for acid stability, making it suitable for oral administration where it must survive stomach acid. The arginine salt form maintains biological activity through the GI tract, making it the preferred form for oral/gut-targeted protocols.
There is no validated human dose for this compound; the following is a commonly cited research convention, not a validated protocol. The standard protocol uses 250-500mcg daily, administered either subcutaneously (acetate form) or orally (arginine salt form). SubQ administration is preferred for systemic tissue repair and localized injury treatment. Oral administration is preferred for GI conditions, gut healing, and gut-brain axis modulation. Both forms can be used simultaneously for maximal coverage.